SCHEMBL2847487

SCHEMBL2847487

COC(=O)/C=C/c1ccc(F)c(N)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.59
APP P05067 1/20 0.59
PTPN1 P18031 1/20 0.56
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
TYR P14679 1/20 0.56
CA7 P43166 1/20 0.56
CA9 Q16790 1/20 0.56
CA14 Q9ULX7 1/20 0.56
EPHX2 P34913 1/20 0.55
KDM4E B2RXH2 4/20 0.54
ALDH1A1 P00352 4/20 0.54
MAPT P10636 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
JAK2 O60674 1/20 0.54
GAA P10253 1/20 0.54
HTT P42858 1/20 0.54
FDPS P14324 1/20 0.51
BACE1 P56817 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2847488 1.00 TTR (0.59) TTRAPPPTPN1CA12CA1
SCHEMBL5225706 0.87 TTR (0.63) TTRAPPPTPN1CA12CA1
SCHEMBL6960198 0.87 TTR (0.63) TTRAPPPTPN1CA12CA1
SCHEMBL6960203 0.87 TTR (0.63) TTRAPPPTPN1CA12CA1
SCHEMBL31560386 0.87 TTR (0.63) TTRAPPPTPN1CA12CA1
SCHEMBL7787485 0.84 TTR (0.59) TTRAPPPTPN1CA12CA1
SCHEMBL11222387 0.84 APP (0.73) TTRAPPPTPN1CA12CA1
SCHEMBL11222383 0.84 APP (0.73) TTRAPPPTPN1CA12CA1
SCHEMBL29913987 0.84 APP (0.73) TTRAPPPTPN1CA12CA1
SCHEMBL16566601 0.83 TTR (0.62) TTRAPPCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8080567-B2 EP2 receptor agonists ASTERAND UK LIMITED (GB) 2011-12-20 US disclosed
US-8080567-B2 EP2 receptor agonists ASTERAND UK LIMITED (GB) 2011-12-20 US disclosed
US-8080567-B2 EP2 receptor agonists ASTERAND UK LIMITED (GB) 2011-12-20 US disclosed
US-20100130556-A1 EP2 RECEPTOR AGONISTS ASTERAND UK LIMITED (GB) 2010-05-27 US disclosed
US-20100130556-A1 EP2 RECEPTOR AGONISTS ASTERAND UK LIMITED (GB) 2010-05-27 US disclosed
US-20100130556-A1 EP2 RECEPTOR AGONISTS ASTERAND UK LIMITED (GB) 2010-05-27 US disclosed
WO-2007017687-A2 EP2 RECEPTOR AGONISTS ASTERAND UK LIMITED (GB) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130556-A1 EP2 RECEPTOR AGONISTS PTGER3, PTGER2, CNR2 TTR 3643/4885APP 4765/4885PTPN1 2475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.